Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 657

1.

[Prostate cancer. Treatment].

Fournier G, Valeri A, Mangin P, Cussenot O.

Ann Urol (Paris). 2004 Oct;38(5):225-58. Review. French.

PMID:
15570706
2.

Endocrine treatment of prostate cancer.

Tammela T.

J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. Epub 2004 Dec 31. Review.

PMID:
15663992
3.
4.

A retrospective study of the treatment of locally advanced prostate cancer by six institutions in eastern and north-eastern Japan.

Hachiya T, Akakura K, Saito S, Shinohara N, Sato K, Harada M, Kato T, Okada K.

BJU Int. 2005 Mar;95(4):534-40.

5.

Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).

Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR; CaPSURE Investigators.

Cancer. 2006 Apr 15;106(8):1708-14.

6.

[GnRH analogs and prostate cancer treatment].

Zerbib M.

Ann Urol (Paris). 2005 Oct;39 Suppl 3:S66-72. Review. French.

PMID:
16302714
7.

Early outcomes of active surveillance for localized prostate cancer.

Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R, Dearnaley D.

BJU Int. 2005 May;95(7):956-60.

8.

Combined androgen blockade: the gold standard for metastatic prostate cancer.

McLeod DG, Crawford ED, DeAntoni EP.

Eur Urol. 1997;32 Suppl 3:70-7. Review.

PMID:
9267789
9.
10.

[Practice guideline 'Prostate cancer: diagnosis and treatment'].

de Reijke TM, Battermann JJ, van Moorselaar RJ, de Jong IJ, Visser AP, Burgers JS.

Ned Tijdschr Geneeskd. 2008 Aug 9;152(32):1771-5. Review. Dutch.

PMID:
18754308
11.

Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.

Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL.

Ann Intern Med. 2008 Mar 18;148(6):435-48. Epub 2008 Feb 4. Review. Erratum in: Ann Intern Med. 2008 Jun 3;148(11):888.

PMID:
18252677
12.
13.

Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen Z, Lief JH, Adamovich E.

Urology. 2005 Jan;65(1):95-100.

PMID:
15667872
14.

Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.

Siddiqui SA, Boorjian SA, Inman B, Bagniewski S, Bergstralh EJ, Blute ML.

J Urol. 2008 May;179(5):1830-7; discussion 1837. doi: 10.1016/j.juro.2008.01.022. Epub 2008 Mar 18.

PMID:
18353378
15.

[Keyrole of endocrinology in the victory against prostate cancer].

Labrie F.

Bull Cancer. 2006 Sep;93(9):949-58. Review. French.

16.

Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.

Moreau JP, Delavault P, Blumberg J.

Clin Ther. 2006 Oct;28(10):1485-508. Review. Erratum in: Clin Ther. 2006 Nov;28(11):1970.

PMID:
17157109
17.

Global update on defining and treating high-risk localized prostate cancer with leuprorelin: an Asian perspective.

Mizokami A, Ueno S, Fukagai T, Ito K, Ehara H, Kinbara H, Origasa H, Usami M, Namiki M, Akaza H.

BJU Int. 2007 Jan;99 Suppl 1:6-9; discussion 17-8. Review.

18.

Hormone therapy for patients with prostate carcinoma.

Klotz L.

Cancer. 2000 Jun 15;88(12 Suppl):3009-14. Review.

PMID:
10898345
19.

[LHRH analogues for the treatment of prostate cancer: an evidence level-based analysis].

Pfitzenmaier J, Altwein JE.

Aktuelle Urol. 2009 Mar;40(2):100-8. doi: 10.1055/s-0028-1098746. Epub 2009 Feb 27. Review. German.

PMID:
19253209
20.

PSA relapse prostate cancer: the importance of tailored therapy.

Aranha O, Vaishampayan U.

Urol Oncol. 2004 Jan-Feb;22(1):62-9. Review.

PMID:
14969807

Supplemental Content

Support Center